Cargando…

Sleeping through the storm: Preventing myelosuppression with quizartinib

Detalles Bibliográficos
Autores principales:	Taylor, Samuel J., Langdon, Wallace Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687601/ https://www.ncbi.nlm.nih.gov/pubmed/29179431 http://dx.doi.org/10.18632/oncotarget.21395

Ejemplares similares

Effect of Food on the Pharmacokinetics of Quizartinib
por: Li, Jianke, et al.
Publicado: (2020)

Repurposing of Ibrutinib and Quizartinib as potent inhibitors of necroptosis
por: Huang, Fangmin, et al.
Publicado: (2023)

Quizartinib (AC220): a promising option for acute myeloid leukemia
por: Zhou, Fang, et al.
Publicado: (2019)

Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
por: Kang, Dongwoo, et al.
Publicado: (2021)

Piperacillin/tazobactam Induced Myelosuppression
por: Lee, Kirsty Wai Chung, et al.
Publicado: (2009)

COVID-19, tuberculosis and poverty: preventing a perfect storm
por: Saunders, Matthew J., et al.
Publicado: (2020)

Crystal Structure of the FLT3 Kinase Domain Bound to the Inhibitor Quizartinib (AC220)
por: Zorn, Julie A., et al.
Publicado: (2015)

Synergistic effect of a novel autophagy inhibitor and Quizartinib enhances cancer cell death
por: Ouchida, Amanda Tomie, et al.
Publicado: (2018)

Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib
por: Yang, Jingmei, et al.
Publicado: (2021)

Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms
por: Patel, Ami B., et al.
Publicado: (2020)

Taming the storm
por: Burstyn-Cohen, Tal, et al.
Publicado: (2021)

Myelosuppression by sunitinib is flt-3 genotype dependent
por: van Erp, N P, et al.
Publicado: (2010)

Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies
por: Li, Jun, et al.
Publicado: (2017)

Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia
por: Kang, Dongwoo, et al.
Publicado: (2020)

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
por: Kumar, R, et al.
Publicado: (2009)

Translational Modeling of Drug‐Induced Myelosuppression and Effect of Pretreatment Myelosuppression for AZD5153, a Selective BRD4 Inhibitor
por: Collins, TA, et al.
Publicado: (2017)

Calming The Storm By Sympatholysis
por: Francis, Johnson, et al.
Publicado: (2011)

The Brazilian orthodontic storm
por: Normando, David
Publicado: (2016)

Antineoplastics: Myelosuppression and COVID-19: case report
Publicado: (2020)

Palbociclib: Myelosuppression and gastrointestinal reactions: case report
Publicado: (2022)

A journey through and beyond a “perfect storm”: the COVID-19 pandemic
por: Filetti, Sebastiano
Publicado: (2020)

Conventional myelosuppressive chemotherapy for non-haematological malignancy disrupts the intestinal microbiome
por: Papanicolas, Lito E., et al.
Publicado: (2021)

Storms & Neuralgia
Publicado: (1879)

Weathering the Storm
por: Cooper, Daniel H., et al.
Publicado: (2023)

A Period of Storm and Stress
por: Cho, Hae-Wol, et al.
Publicado: (2014)

Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia
por: Altman, Jessica K., et al.
Publicado: (2017)

A drug–drug interaction study to assess the potential effect of acid-reducing agent, lansoprazole, on quizartinib pharmacokinetics
por: Li, Jianke, et al.
Publicado: (2019)

Promotion of Myelopoiesis in Myelosuppressed Mice by Ganoderma lucidum Polysaccharides
por: Zhu, Xiao-Ling, et al.
Publicado: (2012)

Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk
por: Nguyen, Christine M., et al.
Publicado: (2011)

Multiple drugs: Aseptic Meningitis and myelosuppression: case report
Publicado: (2022)

Global phosphoproteome analysis of human bone marrow reveals predictive phosphorylation markers for the treatment of acute myeloid leukemia with quizartinib
por: Schaab, C, et al.
Publicado: (2014)

Healthy People 2030: A Compass in the Storm
por: McGinnis, J. Michael
Publicado: (2021)

The Zika Pandemic - A Perfect Storm?
por: Russell, Philip K.
Publicado: (2016)

Weathering the storm; and seeking breaks in the clouds
por: Boyle, Breidge, et al.
Publicado: (2020)

The Brightest Rainbow Follows the Darkest Storm
por: Lake, Douglas
Publicado: (2020)

Myelosuppression in Patients Treated with the Telomerase Inhibitor Imetelstat Is Not Mediated through Activation of Toll-Like Receptors
por: Baerlocher, Gabriela M., et al.
Publicado: (2020)

Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports
por: Martínez-Cuadrón, David, et al.
Publicado: (2020)

P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN FLT3-ITD MUTATED AML
por: Tormo, Mar, et al.
Publicado: (2023)

Prevention Effect of Protopanaxadiol-Type Saponins Saponins and Protopanaxatriol-Type Saponins on Myelosuppression Mice Induced by Cyclophosphamide
por: Zhang, He, et al.
Publicado: (2022)

The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions
por: Bhullar, Jasjeet, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_t7iam12kdmanpq7j23301r25g7